INCY News and Press, Incyte Corporation From 06/04/21

Presentation will be available on demand as part of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting BOSTON, MA and WILMINGTON, DE / ACCESSWIRE / June 4, 2021 / MorphoSys US Inc., a fully owned subsidiary of MorphoSys AG (FSE:MOR) (NASDAQ:MOR), and Incyte (NASDAQ:I...

-- Presentation will be available on demand as part of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting Incyte (NASDAQ:INCY) and MorphoSys US Inc., a fully owned subsidiary of MorphoSys AG (FSE: MOR; NASDAQ:MOR), today announced new three-year follow-up d...

OLUMIANT® Improved Pain, Physical Function and Morning Joint Stiffness in Rheumatoid Arthritis in Phase 3 Post-Hoc Analyses PR Newswire INDIANAPOLIS , June 1, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) will present ...

Incyte has seen some product approvals in 2020, starting to make an initial dent to drive diversification going forward. I like the potential of the company over the long haul, as diversification efforts are still in the early innings. New product approvals and continuation of gro...

- OPTIC trial evaluating response-based dosing regimens of ponatinib in patients with resistant CP-CML met primary endpoint, confirming optimal benefit-risk profile achieved via 45mg/day starting dose reduced to 15mg/day upon response Incyte (Nasdaq:INCY) today announced tha...

Incyte (Nasdaq: INCY) today announced that multiple abstracts highlighting data from its oncology portfolio will be presented during the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, held virtually from June 4-8, 2021. “We look forward to presenti...

Incyte (INCY) announces that its late-stage studies, testing its ruxolitinib treatment in adolescent and adult patients (age ≥12 years) with autoimmune disease vitiligo, met the main goal.Both the TRuE-V1 and TRuE-V2 studies met the primary endpoint, demonstrating significantly mo...

-Primary and key secondary endpoints met in both TRuE-V1 and TRuE-V2 studies -Data will support planned U.S. and EU regulatory submissions for ruxolitinib cream in vitiligo in the second half of 2021 Incyte (Nasdaq:INCY) today announced positive topline results from ...

Incyte (Nasdaq:INCY) today announced that multiple abstracts highlighting data from its oncology portfolio will be presented during the upcoming European Hematology Association (EHA) 2021 Virtual Congress, held virtually from June 9-17, 2021. “We are pleased that data highlig...

Incyte (NASDAQ:INCY) and MorphoSys AG (FSE:MOR; NASDAQ:MOR) today announced that the first patient has been dosed in the pivotal Phase 3 frontMIND study evaluating tafasitamab and lenalidomide in addition to rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHO...